Combining these clinical data and the above in vivo findings, this study suggests the potential of ICB therapy combined with anti-TGF-β therapy for gastric cancer, which may also bring new hope for ICB therapy in gastric cancer. This evidence concerns the gene TGFB1 and gastric cancer.